Published in J Neuroinflammation on October 04, 2011
Risk Factors in Early Multiple Sclerosis (RISEMS) | NCT03586986
The influence of nutritional factors on the prognosis of multiple sclerosis. Nat Rev Neurol (2012) 0.97
Obesity during childhood and adolescence increases susceptibility to multiple sclerosis after accounting for established genetic and environmental risk factors. Obes Res Clin Pract (2014) 0.96
Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert Rev Clin Immunol (2014) 0.94
HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. Nature (2015) 0.94
The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis. Nutr Neurosci (2014) 0.92
Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARβ/δ: a potential therapeutic role for CNS autoimmune disease. Cell Death Dis (2013) 0.90
Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases. Neurotherapeutics (2016) 0.90
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis. J Neuroimmunol (2012) 0.88
Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis. PLoS One (2015) 0.87
The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology (2016) 0.84
The role of epigenetic mechanisms and processes in autoimmune disorders. Biologics (2012) 0.82
Alpha-tocopherol and MRI outcomes in multiple sclerosis--association and prediction. PLoS One (2013) 0.81
Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS. Nat Rev Neurol (2012) 0.80
Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology (2016) 0.78
A lipidomic approach to the study of human CD4(+) T lymphocytes in multiple sclerosis. BMC Neurosci (2015) 0.78
Importance of Apolipoprotein A-I in Multiple Sclerosis. Front Pharmacol (2015) 0.76
Multiple Sclerosis and Obesity: Possible Roles of Adipokines. Mediators Inflamm (2016) 0.76
Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. J Lipid Res (2015) 0.76
Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL. Sci Rep (2017) 0.75
Simultaneous determination of oxysterols, cholesterol and 25-hydroxy-vitamin D3 in human plasma by LC-UV-MS. PLoS One (2015) 0.75
Cardiovascular Dysfunction in Multiple Sclerosis. Maedica (Buchar) (2015) 0.75
Determining Causation from Observational Studies: A Challenge for Modern Neuroepidemiology. Front Neurol (2017) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med (2006) 6.60
Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science (1991) 5.76
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 5.24
Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet (2004) 3.95
Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem (2000) 2.59
HDL cholesterol and protective factors in atherosclerosis. Circulation (2004) 2.25
Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci U S A (1979) 1.96
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology (2008) 1.76
Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr (2005) 1.66
High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev (2002) 1.58
Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology (2010) 1.56
The reelin receptor ApoER2 recruits JNK-interacting proteins-1 and -2. J Biol Chem (2000) 1.52
From endothelial dysfunction to atherosclerosis. Autoimmun Rev (2010) 1.47
Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine (2010) 1.37
Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch Neurol (2007) 1.32
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol (2011) 1.31
Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance. J Cereb Blood Flow Metab (2008) 1.25
Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. Am J Epidemiol (2000) 1.18
Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta (1995) 1.16
Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol (2011) 1.16
Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet (1990) 1.15
Multiple sclerosis as a vascular disease. Neurol Res (2006) 1.12
Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci (2008) 1.10
Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol (2004) 1.10
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol (2010) 1.08
Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology (2009) 1.05
Stimulated T cells generate microparticles, which mimic cellular contact activation of human monocytes: differential regulation of pro- and anti-inflammatory cytokine production by high-density lipoproteins. J Leukoc Biol (2008) 1.03
Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol (2009) 0.97
CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation. Am J Physiol Heart Circ Physiol (2008) 0.97
Lovastatin induces the formation of abnormal myelin-like membrane sheets in primary oligodendrocytes. Glia (2009) 0.94
Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler (2005) 0.91
Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler (2010) 0.91
Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand (2002) 0.90
Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology (2009) 0.89
Expression of apolipoprotein A-I in porcine brain endothelium in vitro. J Neurochem (1994) 0.86
The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon? CNS Neurosci Ther (2010) 0.82
Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler (2008) 0.78
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology (2009) 0.78
Cardiovascular disease complications in systemic lupus erythematosus. Biomark Med (2009) 0.78
Dispersion models and longitudinal data analysis. Stat Med (1999) 0.77
Serum lipoprotein levels in patients with neuromyelitis optica elevated but had little correlation with clinical presentations. Clin Neurol Neurosurg (2010) 0.77
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol (2013) 1.83
Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci (2005) 1.76
Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol (2006) 1.76
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry (2013) 1.69
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.66
Optical coherence tomography in multiple sclerosis. Lancet Neurol (2006) 1.65
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2010) 1.59
Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. J Neuroimaging (2003) 1.51
Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol (2011) 1.51
The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology (2013) 1.48
Information-theoretic metrics for visualizing gene-environment interactions. Am J Hum Genet (2007) 1.47
Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. J Neuroimmunol (2012) 1.46
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.44
Changes of cine cerebrospinal fluid dynamics in patients with multiple sclerosis treated with percutaneous transluminal angioplasty: a case-control study. J Vasc Interv Radiol (2013) 1.43
Semantic integration to identify overlapping functional modules in protein interaction networks. BMC Bioinformatics (2007) 1.43
Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci (2007) 1.39
Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol (2011) 1.29
Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci (2009) 1.28
BioStar models of clinical and genomic data for biomedical data warehouse design. Int J Bioinform Res Appl (2005) 1.28
Risk of bone loss in men with multiple sclerosis. Mult Scler (2004) 1.27
Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage (2011) 1.27
A novel functional module detection algorithm for protein-protein interaction networks. Algorithms Mol Biol (2006) 1.25
AMBIENCE: a novel approach and efficient algorithm for identifying informative genetic and environmental associations with complex phenotypes. Genetics (2008) 1.24
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol (2006) 1.23
Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. Neuroimage (2004) 1.22
Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol (2003) 1.18
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol (2013) 1.16
Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation (2010) 1.11
Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci (2009) 1.11
Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol (2010) 1.10
Recent developments in imaging of multiple sclerosis. Neurologist (2011) 1.09
VizStruct: exploratory visualization for gene expression profiling. Bioinformatics (2004) 1.06
Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. J Clin Exp Neuropsychol (2007) 1.05
Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids (2005) 1.04
Gray matter correlations of cognition in incident Parkinson's disease. Mov Disord (2010) 1.01
Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal Chem (2010) 1.01
Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study. J Magn Reson Imaging (2012) 1.00
An information theoretic approach for analyzing temporal patterns of gene expression. Bioinformatics (2003) 1.00
Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler (2007) 0.99
Brain atrophy and white matter hyperintensities in early Parkinson's disease(a). Mov Disord (2009) 0.98
Leprosy in the era of integration. Indian J Dermatol Venereol Leprol (2009) 0.98
Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol (2007) 0.98
Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol (2009) 0.97
Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC Neurol (2011) 0.96
Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci (2003) 0.96
Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Rev Neurother (2011) 0.96
Cine cerebrospinal fluid imaging in multiple sclerosis. J Magn Reson Imaging (2012) 0.96
Brain iron accumulation in aging and neurodegenerative disorders. Expert Rev Neurother (2012) 0.96
Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation (2009) 0.94
Multiple sclerosis and cerebral endothelial dysfunction: Mechanisms. Pathophysiology (2011) 0.94
Comparison of intravascular ultrasound with conventional venography for detection of extracranial venous abnormalities indicative of chronic cerebrospinal venous insufficiency. J Vasc Interv Radiol (2013) 0.94
Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am J Neuroradiol (2005) 0.94
Information-theoretic gene-gene and gene-environment interaction analysis of quantitative traits. BMC Genomics (2009) 0.93
Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 0.93
Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. Neuroimage (2007) 0.93
Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet (2007) 0.93
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. PLoS One (2013) 0.92
Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. J Neurol Sci (2011) 0.92
Comparison of information-theoretic to statistical methods for gene-gene interactions in the presence of genetic heterogeneity. BMC Genomics (2010) 0.92
Signal abnormalities on 1.5 and 3 Tesla brain MRI in multiple sclerosis patients and healthy controls. A morphological and spatial quantitative comparison study. Neuroimage (2009) 0.92
The interaction index, a novel information-theoretic metric for prioritizing interacting genetic variations and environmental factors. Eur J Hum Genet (2009) 0.92
Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimer's disease. BMC Neurol (2013) 0.92